Good morning, plenty to talk about in this week’s medtech and biotech deal update by Matt Lowdon. Top headlines includes news about clinical care, drug delivery, cancer detection, neurotech and more.
🔔 German Merck has set up a new collaboration with U.K. medtech company Calla Lily Clinical Care to work on its next-generation intravaginal drug delivery approach.
🔔 Bristol Myers Squibb is partnering up with Evinova’s AI clinical development platform across the Big Pharma company’s global portfolio in an effort to improve efficiency and cut costs.
🔔 Gilead Sciences has secured another synthetic lethal therapy, handing over $80 million upfront for the global rights to a clinic-ready cancer drug from China’s Genhouse Bio.
🔔 Madrigal Pharmaceuticals pens $4.4B deal for Ribocure Pharmaceuticals AB Pharmaceuticals’s preclinical siRNA programs in latest Rezdiffra MASH play
🔔 Neupulse, a neurotherapeutics company developing a wristband to manage the symptoms of Tourette Syndrome, has raised £3m in new funding.
🔔 Tozaro, a Sharnbrook company whose ‘Smart Polymer’ technology could significantly reduce the cost of life-saving cell and gene therapies, has raised £6m from investors.
🔔 ILiAD Biotechnologies has closed an oversubscribed $115 million series B fundraise to support the company’s next-generation whooping cough vaccine candidate.
🔔 iGan Partners Leads $10 Million Financing of Exact Imaging, the World’s Leading Prostate Cancer Detection Platform
🔔 Aerska, a startup developing treatments to silence the problematic genes that cause various brain diseases, has raised $39 million in financing
🔔 Xyall, an Eindhoven-based MedTech startup offering an automated tissue dissection solution designed to support molecular pathology workflows, has secured an investment of €7.6 million
🔔 German Biotech Immunic Therapeutics secured US$400 million to conclude phase 3 MS program and prepare for launch
🔔 French biotech GENFIT will receive a $20 million commercial milestone payment after Ipsen reported $208 million in full-year 2025 net sales of Iqirvo in primary biliary cholangitis
🔔 Chemify Limited has struck a deal with Zeon, securing investment from the company’s venture capital wing and signing up to make novel compounds and materials for its new partner.
🔔 France-based 4Moving Biotech raises €12m to prove whether GLP-1 can crack osteoarthritis.
Congratulations to all involved.